학술논문

Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.
Document Type
Article
Source
Investigational New Drugs; Apr2023, Vol. 41 Issue 2, p183-192, 10p
Subject
LUNG cancer
DRUG efficacy
IN vitro studies
GENETIC mutation
PROTEIN kinase inhibitors
EPIDERMAL growth factor receptors
IMMUNOHISTOCHEMISTRY
WESTERN immunoblotting
ANTINEOPLASTIC agents
METASTASIS
LYMPH nodes
CANCER relapse
CYCLIN-dependent kinases
PROTEIN-tyrosine kinase inhibitors
CELL cycle
CELLULAR signal transduction
DRUG synergism
DESCRIPTIVE statistics
RESEARCH funding
CELL lines
LYMPHATICS
PHOSPHORYLATION
PHARMACODYNAMICS
CHEMICAL inhibitors
DISEASE risk factors
EVALUATION
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)